Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Marion Kubista is active.

Publication


Featured researches published by Marion Kubista.


Breast Cancer Research and Treatment | 2002

MMP-2 and MMP-9 Expression in Breast Cancer-Derived Human Fibroblasts is Differentially Regulated by Stromal-Epithelial Interactions

C. F. Singer; Nicole Kronsteiner; Erika Marton; Marion Kubista; Kevin J. Cullen; Kora Hirtenlehner; Michael Seifert; E. Kubista

Tissue remodeling is a key element in the local invasion and metastasis of malignant breast tumors. The degradation of extracellular matrix that is associated with this process is thought to be mediated by a number of Zn2+-dependent matrix metalloproteinases (MMPs). In most cases these enzymes are not produced by the malignant epithelium itself but by adjacent breast stroma, suggesting an important role for cell-cell interactions. We have analyzed Gelatinase A (MMP-2) and Gelatinase B (MMP-9) gene expression in a panel of six breast cancer cell lines and six primary cultures of stromal cells deriving from breast cancer biopsies. With one exception we did not detect MMP-2 or MMP-9 gene expression in any of the established tumor cell lines. Conversely, tumor stroma-derived fibroblasts expressed MMP-2 mRNA, although no MMP-9 mRNA was seen in RNase protection assays. When fibroblasts were cultured in the presence of media conditioned by MCF-7 tumor cells, MMP-2 enzyme production increased but MMP-9 activity remained undetectable. However, when fibroblasts and MCF-7 tumor cells were co-cultured together, MMP-9 was induced. These observations were confirmed by immunocytochemical analysis of co-cultures of MCF-7 and tumor-derived fibroblasts in which MMP-2 and MMP-9 protein expression was confined to stromal cells adjacent to MCF-7 tumor cells. No MMP-2 or MMP-9 staining was detected in monocultures of the two respective cell types. We conclude that MMP-2 expression is present in the stroma of malignant tumors and is increased by paracrine stimulation mediated by soluble factors. In contrast, MMP-9 expression tumor-derived fibroblasts requires direct contact with malignant tumor epithelium.


Oncogene | 2003

Cell size regulation by the human TSC tumor suppressor proteins depends on PI3K and FKBP38

Margit Rosner; Katja Hofer; Marion Kubista; Markus Hengstschläger

TSC1 and TSC2 are responsible for the tumor suppressor gene syndrome tuberous sclerosis (TSC). Mammalian TSC genes have been shown to be involved in cell cycle regulation. Recently, in Drosophila, these data have been confirmed and TSC genes have further been demonstrated to affect cell size control. Here we provide supporting data for the fact that the latter function is conserved in mammals. Human TSC1 and TSC2 trigger mammalian cell size reduction and a dominant-negative TSC2 mutant induces increased size. These effects occur in all cell cycle phases, are dependent on the activity of the phosphoinositide-3-kinase and are abolished by co-overexpression of a dominant-negative Akt mutant. Two independent naturally occurring and disease-causing mutations within the TSC2 gene eliminate tuberins capacity to affect cell size control, emphasizing the relevance of this function for the development of the disease. The same mutations have earlier been shown not to affect tuberins antiproliferative capacity. That the consequences of modulated TSC gene expression on cell proliferation and on cell size can be assigned to separable functions is further supported by two findings: A mutation within the TSC1 gene, earlier shown to still harbor anti-proliferative effects, was found to eliminate the cell size regulating functions. An important mammalian cell size regulator, c-Myc, was found to inhibit tuberins antiproliferative capacity, but to have no effects on tuberin-dependent cell size control. To obtain further mechanistical insights, microarray screens for genes involved in TSC1- or TSC2-mediated cell size effects were performed. Antisense experiments revealed that the so observed regulation of the FK506-binding protein, FKBP38, plays a role in TSC gene-dependent cell size regulation. These data provide new insights into mammalian cell size regulation and allow a better understanding of the function of human TSC genes.


Oncogene | 2002

Brca1 regulates in vitro differentiation of mammary epithelial cells

Marion Kubista; Margit Rosner; E. Kubista; G. Bernaschek; Markus Hengstschläger

Murine Brca1 is widely expressed during development in different tissues. Why alterations of BRCA1 lead specifically to breast and ovarian cancer is currently not clarified. Here we show that Brca1 protein expression is upregulated during mammary epithelial differentiation of HC11 cells, during differentiation of C2C12 myoblasts into myotubes and during neuronal differentiation of N1E-115 cells. Ectopic overexpression of BRCA1 and downregulation of endogenous Brca1 expression specifically affect the regulation of mammary epithelial cell differentiation. Accelerated mammary epithelial cell differentiation upon high ectopic BRCA1 expression is not a consequence of the anti-proliferative capacity of this tumor suppressor and independent of functional p53. Overexpression of the BRCA1 variant lacking the large central exon 11 has no effects on mammary epithelial cell differentiation. These data provide new insights into the cellular role of Brca1.


Mutation Research-reviews in Mutation Research | 2001

Tuberous sclerosis gene products in proliferation control

Markus Hengstschläger; David M. Rodman; Angelina Miloloza; Elke Hengstschläger-Ottnad; Margit Rosner; Marion Kubista

Two genes, TSC1 and TSC2, have been shown to be responsible for tuberous sclerosis (TSC). The detection of loss of heterozygosity of TSC1 or TSC2 in hamartomas, the growths characteristically occurring in TSC patients, suggested a tumor suppressor function for their gene products hamartin and tuberin. Studies analyzing ectopically modulated expression of TSC2 in human and rodent cells together with the finding that a homolog of TSC2 regulates the Drosophila cell cycle suggest that TSC is a disease of proliferation/cell cycle control. We discuss this question including very recent data obtained from analyzing mice expressing a modulated TSC2 transgene, and from studying the effects of deregulated TSC1 expression. Elucidation of the cellular functions of these proteins will form the basis of a better understanding of how mutations in these genes cause the disease and for the development of new therapeutic strategies.


Oncogene | 2001

Tuberous sclerosis causing mutants of the TSC2 gene product affect proliferation and p27 expression.

Thomas Soucek; Margit Rosner; Angelina Miloloza; Marion Kubista; Jeremy Peter Cheadle; Julian Roy Sampson; Markus Hengstschläger

The autosomal dominant disease tuberous sclerosis (TSC) is caused by mutations in either TSC1 on chromosome 9q34, encoding hamartin, or TSC2 on chromosome 16p13.3, encoding tuberin. TSC is characterized by hamartomas that occur in many organs of affected patients and these have been considered to likely result from defects in proliferation control. Although the true biochemical functions of the two TSC proteins have not been clarified, a series of independent investigations demonstrated that modulated hamartin or tuberin expression cause deregulation of proliferation/cell cycle in human, rodent and Drosophila cells. In support of tuberin acting as a tumor suppressor, ectopic overexpression of TSC2 has been shown to decrease proliferation rates of mammalian cells. Furthermore, overexpression of TSC2 has been demonstrated to trigger upregulation of the cyclin-dependent kinase inhibitor p27. We report that three different naturally occurring and TSC causing mutations within the TSC2 gene elliminate neither the anti-proliferative capacity of tuberin nor tuberins effects on p27 expression. For the first time these data provide strong evidence that deregulation of proliferation and/or upregulation of p27 are not likely to be the primary/only mechanisms of hamartoma development in TSC. These results demand reassessment of previous hypotheses of the pathogenesis of TSC.


Breast Cancer Research and Treatment | 2003

Defect of Tumour Necrosis Factor-α (TNF-α) Production and TNF-α-induced ICAM-1 – Expression in BRCA1 Mutations Carriers

Christoph C. Zielinski; Alexandra C. Budinsky; Teresa Wagner; Roswitha M. Wolfram; Wolfgang J. Köstler; Marion Kubista; Thomas Brodowicz; E. Kubista; Christoph Wiltschke

AbstractBackground. Tumour necrosis factor-α (TNF-α) is a potent cytokine secreted primarily by activated cells from the monocyte/macrophage lineage which exhibits various antitumoral effects including the induction of apoptosis, necrosis, activation of lytic effector cells as well as upregulation of the expression of intercellular adhesion molecule-1 (ICAM-1) which is of decisive importance in the interaction with lymphokine activated killer cells. Previous studies from our laboratory have indicated impaired production of TNF-α by monocytes as well as decreased expression of ICAM-1 on monocytes derived from patients with various stages of breast cancer. Methods. In the present experiments, we have assessed spontaneous as well as lipopolysaccharide (LPS)-induced production of TNF-α by as well as expression of ICAM-1 on monocytes derived from healthy females with germline mutations of BRCA1 and from healthy age-matched control females. Results. We report that monocytes derived from healthy women with various germline mutations of BRCA1 had significantly decreased spontaneous (p = 0.03) and LPS-induced (p < 0.001) production of TNF-α, as compared to monocytes derived from healthy age-matched control females. In contrast, no difference in LPS- or TNF-α-induced production of interleukin-6 was found. Whereas unstimulated monocytes derived from healthy women with germline mutations of BRCA1 and from healthy control women had similar expression of ICAM-1, stimulation with cytokines TNF-α and/or interleukin-1 led to a significant increase of ICAM-1 expression on monocytes derived from control females only, but not from BRCA1 germline mutation carriers (p < 0.001). Conclusion. We conclude that the presence of germline mutations of BRCA1 was associated with a selective deficiency in spontaneous and LPS-induced production of TNF-α and of TNF-α-induced ICAM-1 expression on peripheral blood monocytes.


Mutation Research-reviews in Mutation Research | 2002

Brca1 and differentiation

Marion Kubista; Margit Rosner; Angelina Miloloza; Katja Hofer; Andrea-Romana Prusa; Regina Kroiss; Erika Marton; Markus Hengstschläger

Breast cancer is one of the most frequent malignancies affecting women. The human breast cancer gene 1 (BRCA1) gene is mutated in a distinct proportion of hereditary breast and ovarian cancers. Tumourigenesis in individuals with germline BRCA1 mutations requires somatic inactivation of the remaining wild-type allelle. Although, this evidence supports a role for BRCA1 as a tumour suppressor, the mechanisms through which its loss leads to tumourigenesis remain to be determined. Neither the expression pattern nor the described functions of human BRCA1 and murine breast cancer gene 1 (Brca1) can explain the specific association of mutations in this gene with the development of breast and ovarian cancer. Investigation of the role of Brca1 in normal cell differentiation processes might provide the basis to understand the tissue-restricted properties.


Clinical Cancer Research | 2003

Interleukin 1 System and Sex Steroid Receptor Expression in Human Breast Cancer: Interleukin 1α Protein Secretion Is Correlated with Malignant Phenotype

Christian F. Singer; Nicole Kronsteiner; Gernot Hudelist; Erika Marton; Ingrid Walter; Marion Kubista; Klaus Czerwenka; Martin Schreiber; Michael Seifert; E. Kubista


Journal of Neuropathology and Experimental Neurology | 2002

Evidence for separable functions of tuberous sclerosis gene products in mammalian cell cycle regulation.

Angelina Miloloza; Marion Kubista; Margit Rosner; Markus Hengstschläger


Gynecologic Oncology | 2002

Interleukin-1 System and Sex Steroid Receptor Gene Expression in Human Endometrial Cancer

C. F. Singer; Nicole Kronsteiner; Erika Marton; Ingrid Walter; Marion Kubista; Klaus Czerwenka; Martin Schreiber; W. Tschugguel; F. Wieser; E. Kubista

Collaboration


Dive into the Marion Kubista's collaboration.

Top Co-Authors

Avatar

E. Kubista

Medical University of Vienna

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Martin Schreiber

Medical University of Vienna

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Ingrid Walter

University of Veterinary Medicine Vienna

View shared research outputs
Researchain Logo
Decentralizing Knowledge